Immunotherapy Drugs Market Introduction and Overview
According to SPER Market Research, the Global Immunotherapy Drugs Market is estimated to reach USD 674.09 billion by 2033 with a CAGR of 11.75%.
The report includes an in-depth analysis of the Global Immunotherapy Drugs Market, including market size and trends, product mix, applications, and supplier analysis. Drugs used in immunotherapy are used to increase or weaken the immune system in the body. They function by boosting the immune system and inducing an immunological response that facilitates the production of antibodies, and they are mostly used to treat cancer. Malignant or cancer cells are eliminated by antibodies that are produced in reaction to an antigen.
- The safety and tolerability of NC318 as a possible treatment for advanced or metastatic solid tumours would be assessed through a Phase I/II trial (NCT03665285), which NextCure announced will begin in September 2023. The trial comprises evaluations for diseases like ovarian cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma.
- BioNTech SE and the U.K. government signed a Memorandum of Understanding ("MoU") in January 2023 to accelerate clinical studies for tailored mRNA immunotherapies. By the end of 2030, up to 10,000 individuals should be able to receive personalised cancer medicines for their benefit, either through clinical trials or as licensed treatments.
Market Opportunities and Challenges
Opportunities- Innovations in Biotechnology and Customised Medicines Driving the Market for Immunotherapy Drugs Conventional therapies frequently take a one-size-fits-all approach, which might not work for all patients. Conversely, immunotherapy targets particular problems by using the body's immune system, providing a more specialised and efficient form of treatment. The development of immunotherapeutic medications has been greatly aided by biotechnological developments, opening the door to the development of innovative treatments that can specifically target cancer cells, autoimmune conditions, and other illnesses. Personalised immunotherapies have been made possible by advancements in immune system complexity understanding, biomarker identification, and genetic sequencing. Pharmaceutical companies are therefore spending more money on R&D to produce novel medications that can be tailored depending on a person's genetic composition.
Challenges- There are various hurdles facing the market for immunotherapy medications at the moment. Pharmaceutical firms face substantial investment risks due to the high development costs and low success rates of these medications. It will need further research to fully comprehend these innovative medications' long-term safety and efficacy profiles. Immunotherapy has not shown much promise for many cancer types. Therefore, more data is needed to inform combination methods, as monotherapy response rates have been modest thus far. Due to the high expense of these medicines, patient access has also been a challenge.
Market Competitive Landscape
There are a number of significant players in the somewhat fragmented market for immunotherapy medications. To obtain a competitive edge, the market participants are concentrating on R&D, expansions, and the introduction of new products. Leading companies in the industry are Abbott, PerkinElmer Inc, Illumina, Inc, QIAGEN, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Pfizer Inc, Sanofi, Johnson & Johnson Services, Inc, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Type of Drug, By Therapy Area, By End User.
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.
|
| Companies Covered | Abbott, PerkinElmer Inc, Illumina, Inc, QIAGEN, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Pfizer Inc, Sanofi, Johnson & Johnson Services, Inc, AbbVie Inc, Allergan. |
COVID-19 Impact on Global Immunotherapy Drugs Market
The global market for immunotherapy drugs has been significantly impacted by the Covid-19 epidemic. The epidemic has caused delays in clinical trials and research endeavours, as well as disturbances in the manufacturing and supply chain. The epidemic has, however, also raised interest in the use of immunotherapy medications to treat Covid-19, leading to more funding and research being done in this area. Over the course of the projected period, the pandemic is anticipated to propel market expansion due to the increased demand for personalised treatment.
Type Of Drug Insights
The industry has been further subdivided into monoclonal antibodies, immunomodulators, and vaccinations based on the sorts of drugs. Due to expanded R&D in therapeutic monoclonal antibodies and encouraging government initiatives, the monoclonal antibody category accounted for the biggest proportion of more than 76.30% in 2021. For example, the supplementary Biologics License Application for Dupixent (dupilumab), which is approved for the treatment of prurigo nodularis, was accepted by the U.S. FDA in May 2022 for priority review. Throughout the projection period, the vaccines category is anticipated to grow at the quickest rate.
Key Target Audience:
- Pharmaceutical and Biotechnology Companies
- Research and Development Institutes
- Hospitals and Specialty Clinics
- Cancer Treatment Centers
- Immunotherapy Drug Manufacturers
- Contract Research Organizations (CROs)
- Government and Regulatory Agencies
- Healthcare Providers and Practitioners
- Investors and Venture Capitalists
- Patient Advocacy Groups
- Health Insurance Providers
- Academic and Medical Research Centers
- Immuno-oncology Specialists
- Contract Manufacturing Organizations (CMOs)
Our in-depth analysis of the Immunotherapy Drugs Market includes the following segments:
| By Type of Drug: | Monoclonal AntibodiesAdult VaccinesCheckpoint InhibitorsInterferons Alpha and BetaInterleukinsOther Drugs |
| By Therapy Area: | CancerAutoimmune and Inflammatory DiseasesInfectious DiseasesOther Therapy Areas |
| By End User: | HospitalsClinicsOther End Users |
Key Topics Covered in the Report:
- Global Immunotherapy Drugs Market Size (FY’2024-FY’2033)
- Overview of Global Immunotherapy Drugs Market
- Segmentation of Global Immunotherapy Drugs Market By Type of Drug (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins and Other Drugs)
- Segmentation of Global Immunotherapy Drugs Market By Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases and Other Therapy Areas)
- Segmentation of Global Immunotherapy Drugs Market By End User (Hospitals, Clinics and Other End Users)
- Statistical Snap of Global Immunotherapy Drugs Market
- Expansion Analysis of Global Immunotherapy Drugs Market
- Problems and Obstacles in Global Immunotherapy Drugs Market
- Competitive Landscape in the Global Immunotherapy Drugs Market
- Impact of COVID-19 and Demonetization on Global Immunotherapy Drugs Market
- Details on Current Investment in Global Immunotherapy Drugs Market
- Competitive Analysis of Global Immunotherapy Drugs Market
- Prominent Players in the Global Immunotherapy Drugs Market
- SWOT Analysis of Global Immunotherapy Drugs Market
- Global Immunotherapy Drugs Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Immunotherapy Drugs Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Immunotherapy Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Immunotherapy Drugs Market
7. Global Immunotherapy Drugs Market, By Type of Drug USD Million) 2020-2033
7.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2020-2026
7.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Type of Drug, 2027-2033
7.3. Monoclonal Antibodies
7.4. Adult Vaccines
7.5. Checkpoint Inhibitors
7.6. Interferons Alpha and Beta
7.7. Interleukins
7.8. Other Drugs
8. Global Immunotherapy Drugs Market, By Therapy Area (USD Million) 2020-2033
8.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2020-2026
8.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By Therapy Area, 2027-2033
8.3. Cancer
8.4. Autoimmune and Inflammatory Diseases
8.5. Infectious Diseases
8.6. Other Therapy Areas
9. Global Immunotherapy Drugs Market, By End User (USD Million) 2020-2033
9.1. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global Immunotherapy Drugs Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Clinics
9.5. Other End Users
10. Global Immunotherapy Drugs Market Forecast, 2020-2033 (USD Million)
10.1. Global Immunotherapy Drugs Market Size and Market Share
11. Global Immunotherapy Drugs Market, By Region, 2020-2033 (USD Million)
11.1. Global Immunotherapy Drugs Market Size and Market Share By Region (2020-2026)
11.2. Global Immunotherapy Drugs Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America
12. Company Profile
12.1. Abbott
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. PerkinElmer Inc
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Illumina, Inc
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. QIAGEN
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. F. Hoffmann-La Roche Ltd
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Novartis AG
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. AstraZeneca
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Pfizer Inc
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Sanofi
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Johnson & Johnson Services, Inc
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. AbbVie Inc
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Allergan
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links